Nimodipine is indicated to improve neurological outcome after subarachnoid hemorrhage (ruptured blood vessels in the brain).
To report any serious adverse events associated with the use of this drug, please contact the FDA MedWatch program using the contact information at the bottom of this page.
FDA Drug Safety Communication: Serious medication errors from intravenous administration of nimodipine oral capsules
FDA Drug Safety Podcast for Healthcare Professionals: Serious medication errors from intravenous administration of nimodipine oral capsules[ARCHIVED]
- Nimodipine (marketed as Nimotop) - Healthcare Professional Sheet [ARCHIVED]